The Trade

The market prices ≈41% probability of positive STRO-004 clinical data. We see 55%. The edge comes from management language, insider buying with data visibility, and cross-ticker target validation. 14 points of probability edge on a binary catalyst 27 days out. Options are illiquid (11 total OI across all expirations) — equity is the vehicle.

The Scenarios

Everything hinges on the AACR April 20 poster: STRO-004 Phase 1 clinical data in TF-expressing solid tumors.

EV: $24.25 (+13.7%). If positive (55%): conditional EV $34.32 (+61%). If negative (45%): conditional EV $11.94 (-44%).

The Insider Signal

Jane Chung, CEO, bought STRO at $0.80 in October 2025. Then she bought again at $21.33 in March 2026.

Buying at the 52-week low is common — it's cheap, it signals confidence, it costs nothing. Buying again at 25x your prior entry, near the 52-week high, after seeing three cohorts of Phase 1 data — that's a different act. That's writing a personal check because you know what the AACR poster will show.

She's not alone. Five insiders bought open-market over six months: CEO Chung, Director Matsui (50,000 shares at $0.80), General Counsel Pauling, CSO Gerber, and CFO Chow. All at the lows. Then Chung, Pauling, and Gerber bought again at $21+ in March. Cluster buying at both ends of the price range with data visibility into Cohort 1-3 results.

One detail: the February 2026 secondary offering includes a 90-day insider lockup expiring ~May 12. These insiders bought in March knowing they can't sell until after AACR. Locked in through the catalyst.

What Management Says When They've Seen the Data

Biotech IR operates in a narrow corridor between legal liability and investor expectations. Every word of data guidance is reviewed by counsel. The language spectrum runs from "safety and tolerability" (saw nothing) to "preliminary clinical activity" (saw something).

After three dose cohorts completed, Sutro's March 23 press release: "Initial clinical data are expected in mid-2026, including safety and tolerability. Sutro also expects to share pharmacokinetic exposure and potentially early signs of activity."

You don't add "potentially early signs of activity" after seeing three cohorts if you saw nothing. You say "safety and PK." They didn't.

The AACR poster title corroborates: "Phase 1 open-label study to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity of STRO-004." Poster titles are selected by investigators and approved by the AACR committee. Including "preliminary anti-tumor activity" means there IS activity data to present. The question is magnitude.

CEO quote after seeing the data: "initial data that we believe will showcase the vast potential of our proprietary ADC platform."

The Competitive Landscape Validates the Design

STRO-004 targets Tissue Factor (TF/CD142) with an exatecan payload. Three things happened in the TF ADC landscape that the market hasn't connected:

The target is validated. Tivdak (first TF ADC, Pfizer/Genmab) was approved 2021, did $164M in 2025. Two more TF ADCs are in Phase 3: Lepu's MRG004A (33% ORR in pancreatic cancer, ASCO 2024) and Evopoint's XNW28012 (Chinese Breakthrough Therapy Designation). "Does TF work?" is answered.

The payload generation is shifting. Exelixis killed their MMAE-based TF ADC (XB002) in August 2024 — concluded it couldn't beat Tivdak. Then started building XB371, a Topo1i-payload TF ADC. Same payload class as STRO-004. Exelixis independently concluded the path to a better TF ADC runs through exatecan-class payloads. That's exactly what Sutro built.

STRO-004 leads Gen 2. Among Topo1i/exatecan TF ADCs, STRO-004 is the only one with three completed human dose cohorts. Exelixis XB371 is preclinical. Adcendo's ADCE-T02 is early Phase 1 at best. First-mover in the payload generation the industry is converging on.

If STRO-004 shows responses at AACR, the market won't debate whether TF works — that's settled. The debate becomes best-in-class. DAR8, site-specific conjugation, and Fc-silent design (addressing Tivdak's hemorrhage boxed warning) argue STRO-004 wins that debate.

The Valuation Gap

March 2025: Taiho acquired Araris Biotech for $400M upfront + $740M milestones ($1.14B total). Araris had zero clinical data. Pure platform deal — next-gen linker technology.

Sutro has a clinical-stage lead (STRO-004, 3 cohorts complete), a validated cell-free manufacturing platform, an active $90M+ Astellas partnership with $1B+ in biobucks, dual-payload capability, and six AACR presentations. Market cap: $300M.

The counter is real: private deals carry control premiums, and one comp isn't a basket. But 3-4x between Sutro and a company with less data is a gap that suggests the market is underpricing something. If AACR data confirms efficacy, $800M-$1B is defensible on deal comps — 2.5-3.5x from here.

The Factor Profile

82% idiosyncratic variance (above 75% target). R-squared 18% — factors explain almost nothing. XBI beta 1.92 drives 19% of variance with no edge (unhedged passive biotech beta, acceptable given idio dominance).

Edge concentrates in two places: clinical data signals (50% of idio value, STRONG edge from language decoding + cross-ticker validation) and insider buying pattern (15% of idio, STRONG edge from primary source Form 4 analysis). Combined edge-weighted alpha: 61% of total variance.

The Bear Case, Honestly

Up 177% in a year. We're looking at $21, not $5. The restructuring, the offering, the AACR catalyst — some of this is priced.

Two dead partnerships. Ipsen terminated STRO-003 (ROR1 ADC) June 2025. Merck dormant at $0 FY2025 revenue. If 2 of 3 partners walk, maybe the platform has execution problems one poster can't fix. Bull read: different targets, competitive dynamics, not platform quality. Bear read: pattern.

Small N. Three cohorts of 3-6 patients each. Maybe 9-18 total, at early dose levels that may be sub-therapeutic. "Potentially early signs of activity" could mean one equivocal scan. We don't know the dose levels relative to the NHP MTD (50 mg/kg) — this is the single biggest unknown in the thesis. If cohorts are at 1-5 mg/kg, seeing real responses is unlikely regardless of management language.

The street is split. Mean analyst target $21.25 = current price. HC Wainwright (biotech specialist) at Neutral/$10. BofA at Underperform. Bears include people who cover ADCs for a living.

Exatecan is crowding. Daiichi Sankyo has 7 DXd ADCs. Chinese biotechs dominate global ADC licensing (≈90%). AACR 2026 features 18 dual-payload projects. Platform showcases are table stakes, not differentiators. Sutro's moat is the manufacturing platform, not the payload class.

Blackstone deferred royalty. $219.5M growing $38M/year non-cash. Constrains long-term equity value even if the platform succeeds.

Timing

NOW - April 4:     Accumulation window
~April 7-11:       AACR abstracts online — HARD ENTRY DEADLINE
                    (if abstract contains data, stock moves here, not April 20)
April 17:          Options expiry (does NOT capture catalyst)
April 19:          STRO-004 preclinical oral + Astellas oral — first data drop
April 20:          STRO-004 Phase 1 clinical poster — THE EVENT
~May 12:           Insider lockup expires

April 19 is underappreciated. The preclinical oral — "superior efficacy across TF-expressing solid tumors" — drops the day before the clinical poster. Two catalyst days, not one.

Conviction

The strongest signal is the simplest. Jane Chung bought at $0.80 then bought again at $21.33 after seeing three cohorts of Phase 1 data. She has better information than we do, and she's writing personal checks at current prices.

The language corroborates. The competitive landscape corroborates. The deal comps provide the magnitude.

14 probability points of edge. If AACR delivers, the platform re-rates. If it doesn't, we're wrong and we move on.

Evidence

Bull:

Bear: